| Literature DB >> 31759344 |
Elpidoforos S Soteriades1,2, Jaeyoung Kim2,3, Costas A Christophi2,4,5, Stefanos N Kales2,6.
Abstract
OBJECTIVE: A systematic literature review and meta-analysis was conducted on the association between firefighting and cancer.Entities:
Keywords: Cancer Incidence; Firefighters; Meta-analysis; Systematic review; mortality
Mesh:
Year: 2019 PMID: 31759344 PMCID: PMC7063017 DOI: 10.31557/APJCP.2019.20.11.3221
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Pooled Estimates for the Association of Firefighting with Different Cancers
| Cancer Site | Risk Estimate (95% CI) [number of studies] | ||
|---|---|---|---|
| Incidence | Mortality | Incidence and Mortality | |
| Cancer sites with statistically significant findings and generally consistent point estimates | |||
| Brain and CNS | |||
| Good Studies only | 0.87 (0.55 – 1.37) [4] | 1.31 (0.85 – 2.01) [9] | 1.19 (0.84 – 11.68) [11] |
| Good and Adequate | 1.27 (0.89 – 1.80) [7] | 1.24 (0.86 – 1.77) [11] | 1.25 (0.99 – 1.59) [16] |
| All Studies | 1.27 (0.89 – 1.80) [7] | 1.26 (1.02 – 1.55)* [18] | 1.26 (1.06 – 1.50)* [24] |
| Non-Hodgkin’s Lymphoma | |||
| Good Studies only | 1.11 (0.73 – 1.68) [3] | 1.25 (0.73 – 2.61) [2] | 1.20 (0.90 – 1.61) [5] |
| Good and Adequate | 1.07 (0.91 – 1.24) [5] | 1.40 (0.99 – 1.96) [3] | 1.12 (0.97 – 1.28) [8] |
| All Studies | 1.36 (0.85 – 2.18) [6] | 1.44 (1.27 – 1.63) ** [7] | 1.37 (1.14 – 1.64) ** [13] |
| Skin Melanoma | |||
| Good Studies only | 1.20 (0.86 – 1.68) [4] | 0.69 (0.22 – 2.18) [2] | 1.15 (0.83 – 1.59) [5] |
| Good and Adequate | 1.10 (0.77 – 1.58) [6] | 1.40 (0.46 – 4.30) [3] | 1.22 (0.87 – 1.71) [8] |
| All Studies | 1.10 (0.77 – 1.58) [6] | 1.62 (1.26 – 2.10) ** [6] | 1.34 (1.09 – 1.65)* [11] |
| Colorectal | |||
| Good Studies only | 1.04 (0.91 – 1.89) [13] | 1.21 (1.07 – 1.36)* [25] | 1.14 (1.03 – 1.25)* [14] |
| Good and Adequate | 1.05 (0.93 – 1.19) [17] | 1.21 (1.08 – 1.35)* [27] | 1.13 (1.04 – 1.24)* [18] |
| All Studies | 1.08 (0.95 – 1.22) [18] | 1.16 (1.07 – 1.25)** [42] | 1.13 (1.06 – 1.21)* [28] |
| Colon | |||
| Good Studies only | 1.10 (0.91 – 2.48) [4] | 1.14 (0.93 – 1.39) [9] | 1.11 (0.94 – 1.30) [10] |
| Good and Adequate | 1.22 (1.05 – 1.42)* [6] | 1.14 (0.93 – 1.39) [9] | 1.18 (1.04 – 1.34)* [13] |
| All Studies | 1.26 (1.10 – 1.44)**[7] | 1.10 (0.99 – 1.26) [16] | 1.15 (1.05 – 1.26)* [21] |
| Rectal | |||
| Good Studies only | 1.06 (0.80 – 1.42) [4] | 1.34 (1.05 – 1.72)* [8] | 1.22 (1.01 – 1.47)* [10] |
| Good and Adequate | 0.99 (0.78 – 1.24) [5] | 1.34 (1.08 – 1.67)* [9] | 1.16 (0.99 – 1.36) [12] |
| All Studies | 0.99 (0.78 – 1.24) [5] | 1.25 (1.09 – 1.44) ** [16] | 1.18 (1.04 – 1.34)* [19] |
| Bladder | |||
| Good Studies only | 1.18 (0.97 – 1.43) [6] | 1.39 (0.91 – 2.11) [9] | 1.24 (0.98 – 1.57) [14] |
| Good and Adequate | 1.06 (0.88 – 1.27) [9] | 1.38 (0.98 – 1.95) [11] | 1.20 (0.98 – 1.45) [19] |
| All Studies | 1.06 (0.88 – 1.27) [9] | 1.28 (1.05 – 1.56)* [17] | 1.18 (1.01 – 1.36)* [25] |
| Prostate | |||
| Good Studies only | 1.14 (0.90 – 1.45) [7] | 1.20 (0.76 – 1.90) [9] | 1.17 (0.90 – 1.53) [15] |
| Good and Adequate | 1.15 (1.01 – 1.32)* [9] | 1.20 (0.76 – 1.90) [9] | 1.19 (0.98 – 1.44) [17] |
| All Studies | 1.21 (1.04 – 1.42)* [11] | 1.27 (1.01 – 1.61)* [16] | 1.26 (1.10 – 1.45)** [26] |
| Testicular | |||
| Good Studies only | 1.58 (1.23 – 2.03) ** [3] | 2.52 (0.67 – 9.49) [1] | 1.61 (1.26 – 2.06) ** [4] |
| Good and Adequate | 1.73 (1.31 – 2.27) ** [7] | 2.52 (0.67 – 9.49) [1] | 1.73 (1.35 – 2.23) ** [8] |
| All Studies | 1.73 (1.31 – 2.27) ** [7] | 1.63 (0.60 – 4.40) [3] | 1.68 (1.35 – 2.08) ** [10] |
Risk estimates and confidence intervals in all tables were derived using STATA; * P < 0.05; ** P < 0.001
Pooled Estimates for the Association of Firefighting with Certain Cancers
| Risk Estimate (95% CI) [number of studies] | |||
|---|---|---|---|
| Cancer Site | Incidence | Mortality | Incidence and Mortality |
| Cancer sites with some statistically significant findings | |||
| Leukemia | |||
| Good Studies only | 0.82 (0.55 – 1.23) [2] | 0.96 (0.74 – 1.26) [5] | 0.92 (0.73 – 1.15) [7] |
| Good and Adequate | 0.95 (0.70 – 1.30) [4] | 0.98 (0.76 – 1.26) [6] | 1.02 (0.88 – 1.19) [10] |
| All Studies | 1.08 (0.77 – 1.52) [5] | 1.19 (1.04 – 1.36)* [14] | 1.14 (0.99 – 1.30) [19] |
| Hodgkin’s Lymphoma | |||
| Good Studies only | 0.77 (0.41 – 1.45) [2] | 0.88 (0.25 – 3.02) [2] | 0.79 (0.45 – 1.39) [4] |
| Good and Adequate | 1.04 (0.57 – 1.89) [3] | 0.88 (0.25 – 3.02) [2] | 0.99 (0.61 – 1.61) [5] |
| All Studies | 1.04 (0.57 – 1.89) [3] | 1.80 (1.27 – 2.56)** [7] | 1.51 (1.13 – 2.02)* [10] |
| Lymphosarcoma and Reticulosarcoma | |||
| Good Studies only | 1.01 (0.57 – 1.75) [1] | 0.69 (0.22 – 2.18) [2] | 1.08 (0.71 – 1.66) [3] |
| Good and Adequate | 1.01 (0.57 – 1.75) [1] | 1.21 (0.62 – 2.34) [2] | 1.08 (0.71 – 1.66) [3] |
| All Studies | 1.01 (0.57 – 1.75) [1] | 1.58 (1.09 – 2.27)* [5] | 1.38 (1.01 – 1.87)* [6] |
| Multiple Myeloma | |||
| Good Studies only | 0.70 (0.10 – 2.60) [1] | 1.68 (0.90 – 3.12) [1] | 1.68 (0.90 – 3.12) [1] |
| Good and Adequate | 0.96 (0.72 – 1.28) [3] | 1.68 (0.90 – 3.12) [1] | 1.09 (0.75 – 1.57) [4] |
| All Studies | 0.96 (0.72 – 1.28) [3] | 1.28 (1.03 – 1.58)* [8] | 1.17 (0.98 – 1.38) [10] |
| Pancreatic | |||
| Good Studies only | 0.89 (0.73 – 1.08) [7] | 0.99 (0.79 – 1.24) [8] | 0.96 (0.80 – 1.17) [12] |
| Good and Adequate | 0.89 (0.73 – 1.08) [7] | 0.99 (0.80 – 1.22) [9] | 0.93 (0.81 – 1.08) [15] |
| All Studies | 0.89 (0.73 – 1.08) [7] | 1.14 (1.01 – 1.28)* [15] | 1.06 (0.96 – 1.18) [21] |
| Kidney | |||
| Good Studies only | 0.74 (0.52 – 1.07) [3] | 1.08 (0.58 – 2.02) [7] | 0.95 (0.61 – 1.47) [10] |
| Good and Adequate | 1.01 (0.80 – 1.27) [5] | 1.08 (0.58 – 2.02) [7] | 1.05 (0.79 – 1.38) [12] |
| All Studies | 1.22 (0.76 – 1.95) [6] | 1.29 (1.06 – 1.57)* [13] | 1.25 (1.02 – 1.53)* [19] |
* P < 0.05; ** P < 0.001
Pooled Estimates for the Association of Firefighting with Different Cancers
| Risk Estimate (95% CI) [number of studies] | |||
|---|---|---|---|
| Cancer Site | Incidence | Mortality | Incidence and Mortality |
| Cancer sites with no statistically significant associations | |||
| Oral and Pharyngeal | |||
| Good Studies only | 0.80 (0.50 – 1.28) [2] | 1.07 (0.70 – 1.63) [6] | 0.96 (0.68 – 1.34) [8] |
| Good and Adequate | 0.80 (0.50 – 1.28) [2] | 1.08 (0.75 – 1.56) [7] | 0.95 (0.70 – 1.30) [9] |
| All Studies | 0.80 (0.50 – 1.28) [2] | 1.04 (0.84 – 1.30) [11] | 0.94 (0.77 – 1.15) [13] |
| Laryngeal | |||
| Good Studies only | 0.77 (0.50 – 1.18) [2] | 0.68 (0.36 – 1.30) [4] | 0.74 (0.52 – 1.06) [6] |
| Good and Adequate | 0.77 (0.50 – 1.18) [2] | 0.68 (0.36 – 1.30) [4] | 0.74 (0.52 – 1.06) [6] |
| All Studies | 1.21 (0.53 – 2.76) [3] | 0.94 (0.67 – 1.31) [8] | 1.02 (0.74 – 1.41) [11] |
| Lung | |||
| Good Studies only | 0.78 (0.52 – 1.18) [7] | 0.96 (0.82 – 1.11) [9] | 0.88 (0.74 – 1.05) [14] |
| Good and Adequate | 0.85 (0.66 – 1.09) [10] | 0.98 (0.85 – 1.13) [10] | 0.92 (0.81 – 1.05) [18] |
| All Studies | 0.85 (0.66 – 1.09) [10] | 0.99 (0.90 – 1.09) [17] | 0.95 (0.86 – 1.04) [25] |
| Esophageal | |||
| Good Studies only | 0.89 (0.49 – 1.62) [3] | 0.90 (0.47 – 1.71) [5] | 0.93 (0.60 – 1.43) [8] |
| Good and Adequate | 1.09 (0.75 – 1.58) [5] | 0.90 (0.47 – 1.71) [5] | 1.02 (0.74 – 1.40) [10] |
| All Studies | 1.09 (0.75 – 1.58) [5] | 1.02 (0.80 – 1.31) [10] | 1.06 (0.87 – 1.29) [15] |
| Stomach | |||
| Good Studies only | 0.87 (0.45 – 1.70) [5] | 1.03 (0.85 – 1.24) [10] | 0.99 (0.80 – 1.25) [13] |
| Good and Adequate | 0.87 (0.60 – 1.26) [7] | 1.03 (0.85 – 1.24) [10] | 0.96 (0.80 – 1.16) [15] |
| All Studies | 0.87 (0.60 – 1.26) [7] | 1.05 (0.91 – 1.21) [17] | 0.98 (0.84 – 1.13) [22] |
| Liver and Gallbladder | |||
| Good Studies only | 0.77 (0.41 – 1.45) [2] | 1.10 (0.80 – 1.53) [7] | 1.02 (0.77 – 1.37) [8] |
| Good and Adequate | 0.91 (0.56 – 1.47) [3] | 1.10 (0.80 – 1.53) [7] | 1.04 (0.79 – 1.36) [9] |
| All Studies | 0.91 (0.56 – 1.47) [3] | 1.14 (0.94 – 1.38) [13] | 1.11 (0.93 – 1.32) [15] |
| Lymphatic and Hematopoietic | |||
| Good Studies only | 0.32 (0.08 – 1.25) [1] | 0.92 (0.67 – 1.26) [7] | 0.85 (0.61 – 1.20) [7] |
| Good and Adequate | 0.32 (0.08 – 1.25) [1] | 0.84 (0.62 – 1.14) [8] | 0.80 (0.59 – 1.10) [8] |
| All Studies | 0.32 (0.08 – 1.25) [1] | 1.11 (0.91 – 1.35) [13] | 1.07 (0.87 – 1.32) [13] |
| Urinary | |||
| Good Studies only | 1.02 (0.33 – 3.12) [1] | 0.60 (0.23 – 1.55) [2] | 0.67 (0.34 – 1.35) [3] |
| Good and Adequate | 1.02 (0.33 – 3.12) [1] | 0.85 (0.47 – 1.56) [4] | 0.86 (0.53 – 1.34) [5] |
| All Studies | 1.02 (0.33 – 3.12) [1] | 1.12 (0.59 – 2.12) [5] | 1.10 (0.63 – 1.91) [6] |
| Skin cancer * | |||
| Good Studies only | 0.98 (0.60 – 1.59) [3] | 1.08 (0.78 – 1.50) [4] | 1.04 (0.82 – 1.31) [7] |
| Good and Adequate | 0.98 (0.60 – 1.59) [3] | 1.08 (0.78 – 1.50) [4] | 1.04 (0.82 – 1.31) [7] |
| All Studies | 0.98 (0.60 – 1.59) [3] | 1.34 (0.98 – 1.83) [8] | 1.18 (0.92 – 1.52) [11] |
*, Includes Melanoma and Non-melanoma skin cancer.